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Trichomonas vaginalis is the causative agent of trichomoniasis. The genetic characterisation 
of T. vaginalis isolates reveals significant genetic diversity in this organism. Data on the 
prevalence of different genotypes of T. vaginalis in South African populations is lacking. This 
study investigated the diversity of T. vaginalis in a pregnant population in South Africa. In this 
study, 362 pregnant women from the King Edward VIII hospital in Durban, South Africa 
provided vaginal swabs to be tested for the presence of T. vaginalis. T. vaginalis was detected 
using the TaqMan assay using commercially available primers and probes specific for this 
protozoa (Pr04646256_s1). The actin gene from T. vaginalis was amplified with gene specific 
primers. The actin amplicons were digested with HindII, MseI and RsaI and the banding 
patterns were compared across the three digests for assignment of genotypes. Phylogenetic 
analysis was conducted using MEGA. The prevalence of T. vaginalis in the study population 
was 12.9% (47/362). Genotype G was the most frequent genotype in our study population. 
Genotypes H and I were detected in one sample each. According to the multiple sequence 
alignments and phylogenetic analysis, a level of diversity was observed across and within 
genotypes. Four different single nucleotide changes in the actin gene were detected. Sample 
TV358 (genotype H) contained a single amino acid substitution from Glutamine to Lysine. 
Sample TV184 (genotype G) contained a single amino acid substitution from Glutamic acid to 
Arginine. Sample TV357 (genotype G) contained two amino acid substitutions, Arginine to 
Leucine and Glycine to Aspartic acid. Three different genotypes were observed in the pregnant 
population. Diversity was observed across and within genotypes. The observed diversity can 
be challenging for future vaccine design and development of antigen-based rapid diagnostic 
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Trichomonas vaginalis is referred to as an anaerobic, flagellated protozoan and a causative 
agent of trichomoniasis. This particular parasite can be transmitted via sexual intercourse from 
host to host (Conrad et al., 2012). Trichomoniasis is considered to be the most prevalent non-
viral sexually transmitted infection (STI) worldwide affecting individuals of all ages, ethnicity 
and socioeconomic groups (Napierala et al., 2010; Conrad et al., 2012; Apalata et al., 2014, 
Naidoo, 2015). The World Health Organization (WHO) estimated that in the year 2016 
approximately 156 million new cases of trichomoniasis was reported in adults aged between 
15-49 years (Rowley et al., 2019). T. vaginalis can infect both males and females, however the 
infection rate is much higher in women (Khalili et al., 2017).  
Trichomoniasis has been reported to have over 276.4 million reported infections worldwide 
(Ramjee et al., 2015). Out of the 276 million cases, 25 million cases have been reported in 
pregnant women (Salakos et al., 2018). Pregnant women infected with T. vaginalis have a 
higher risk of preterm delivery, since T. vaginalis causes the premature rupture of membranes. 
A previous study has shown that pregnant women infected with T. vaginalis have a 30% risk 
of preterm delivery or delivering infants who have a low-birth weight (Cotch et al., 1997).        
T. vaginalis infection also contributes to the increase in mother-to-child transmission of HIV 
(Kock et al., 2011). 
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Many molecular based techniques have been used in the past in order to distinguish T. vaginalis 
strains which include Microsatellite genotyping, Multilocus sequence typing (MLST), 
polymerase chain reaction (PCR)-hybridization, random amplification of polymorphic DNA 
(RAPD), PCR-size polymorphism as well as PCR-restriction fragment length polymorphism 
(PCR-RFLP) (Khalili et al., 2017). Actin is one of the structural proteins present in T. vaginalis. 
This protein is well-conserved and ubiquitous in nature, thereby making it a likely option for 
intra-species molecular identification (Meade and Carlton, 2013). To validate the use of this 
protein for the genetic characterisation of T. vaginalis, Crucitti et al., 2008, conducted a study 
using PCR-RFLP, to identify different genotypes of T. vaginalis based on the actin gene. The 
study identified eight T. vaginalis actin genotypes among 151 isolates obtained from the 
Democratic Republic of Congo and Zambia (Crucitti et al., 2008). Other studies conducted in 
Kenya and Iran have successfully identified distinct genotypes of T. vaginalis based on 
digestion of the actin gene (Matini et al., 2017; Masha et al., 2017; Khalili et al., 2017; Oliaee 
et al., 2017).  
Currently, there is a lack of data on the circulating genotypes of T. vaginalis in South African 
populations, particularly pregnant women. In this study, PCR-RFLP of the actin gene was 
performed in order to identify the different genotypes circulating in our population. 
Identification of the genotypes will provide a snapshot into the molecular epidemiology of       
T. vaginalis in our region which can be used a foundation for larger epidemiological studies on 








CHAPTER 2  
LITERATURE REVIEW 
 
1.1 Epidemiology of Trichomonas vaginalis  
Trichomonas vaginalis is referred to as an anaerobic, flagellated protozoan and the causative 
agent of trichomoniasis. T. vaginalis is known to be a haploid eukaryotic parasite, highly motile 
and aero-tolerant which simply means that it is unable to use oxygen as a source of growth but 
can tolerate its presence. This particular parasite can be transmitted via sexual intercourse from 
host to host (Conrad et al., 2012). T. vaginalis is known to form a linear, double-stranded RNA 
virus referred to as the T. vaginalis virus (TVV) which may be associated with its virulence 
(Goodman et al., 2011; Conrad et al., 2012).  
Trichomoniasis is considered to be the most prevalent non-viral sexually transmitted infection 
(STI) worldwide affecting individuals of all ages, ethnicity and socioeconomic groups 
(Napierala et al., 2010; Conrad et al., 2012; Apalata et al., 2014, Naidoo, 2015).  In 2012, the 
World Health Organization (WHO) reported a total number of 142.7 million cases for 
trichomoniasis infection (Figure 1). According to Figure 1, the highest number of cases of 
trichomoniasis was reported for the Western Pacific region (45.3 million cases), followed by 
African region (37.4 million cases), American region (27.4 million cases), Eastern 
Mediterranean region (15.6 million cases), South-East Asia region (13.2 million cases) and 





Figure 1: WHO regional estimates of new cases per million of the four curable sexually 
transmitted infections. Within the African region, the highest number of infections are reported 
for T. vaginalis (Unemo et al., 2017). 
A study conducted by Newman et al., 2015, assessed the global prevalence for trichomoniasis 
amongst women to be approximately 5.0% (4.0-6.4%) whereas for men it was estimated to be 
approximately 0.6% (0.4-0.8%) (Newman et al., 2015). The lower prevalence of the infection 
in males is due to the presence of zinc which is found in the prostatic fluid.  Zinc is known to 
have anti-trichomonal activity in vitro eventually resulting in the inhibition of T. vaginalis in 
vivo (Krieger and Rein, 1982).   
Several studies have reported prevalence data on T. vaginalis from South African populations. 
These studies are described below.  Data obtained from a study conducted by Moodley et al., 
2003, on women attending a reproductive health clinic in KwaZulu-Natal reported a prevalence 
of 29% for T. vaginalis. Another study by Lewis et al., 2013 involving both men and women 
from a primary health care clinic in Johannesburg, found that 23.6% of the women and 6.1% 
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of the men were infected with T. vaginalis.  In another study conducted on female sex workers 
from Durban, the prevalence rate for T. vaginalis was 20.3 % (Mlisana et al., 2012). Two recent 
studies conducted by our research group reported prevalence rates of 10% and 13%, 
respectively for T. vaginalis in antenatal women from Durban (Dessai et al., 2020, Mabaso et 
al., 2020).    
Several studies have identified risk factors for prevalent T. vaginalis infection in women.  Risk 
factors include having sex without a condom, ethnicity (more prevalent within the black race 
group), multiple sexual partners, greater years of sexual activity, history of STIs and previous 
infection with T. vaginalis (Helms et al., 2008; Krashin et al., 2010). Studies conducted by 
Abbai et al., 2013 and Naidoo et al., 2014 in women from KwaZulu-Natal, South Africa found 
that women 25 years and younger, were at a higher risk of acquiring STIs. Reasons related to 
younger women being more at risk for infection included behavioural and biological factors 
(Abbai et al., 2013). Abbai et al., 2013, also found that women who were previously diagnosed 
with an STI have a much greater risk for future infection. Other risk factors for acquiring 
infection included having a lower level of education (Cudmore and Garber, 2010; Abbai et al., 
2013). A study conducted by Eshete et al., 2013 in pregnant women from Ethiopia showed that 
dysuria, dyspareunia, abnormal vaginal discharge as well as educational status did play a 
critical role in respect to the increased number of T.vaginalis infections. Mabaso et al., 2020 
also identified abnormal vaginal discharge as a risk factor for T.vaginalis infections in pregnant 
women.   
Numerous studies have also shown a positive association between T. vaginalis infection and   
human immunodeficiency virus (HIV) acquisition. T. vaginalis increases the risk of acquiring 
HIV by an estimated 2 fold (Davis et al., 2016). This particular parasite has also been associated 
with an increase in HIV transmission from mother to child (Garber, 2005). The biological 
reasons for T. vaginalis increasing HIV transmission amongst women could be due to two 
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reasons, (1) the accumulation of both macrophages and CD4 (cluster of differentiation 4) 
lymphocytes which are HIV target cells and (2) disruption of the vaginal epithelial barrier 
enabling the movement of HIV into the laminae propriae (Garber, 2005, Abbai et al., 2016). 
Due to the high prevalence of T. vaginalis this ultimately leads to a significantly higher number 
of new HIV infections globally (Conrad et al., 2012). 
Additionally, in women with trichomoniasis, there is a risk of co-infection with bacterial 
vaginosis (BV) since T. vaginalis has the capability of creating an anaerobic environment 
resulting in an increase in vaginal pH, thus changing the vaginal flora (Cudmore et al., 2004). 
Gatski et al., 2011, reported a co-infection rate of 17.5% for T. vaginalis and BV. A later study 
conducted by Sobel et al., 2013, reported a co-infection rate of approximately 70% for T. 
vaginalis and BV. A study conducted by Abbai et al., 2016A, in South African women showed 
a significant association between baseline BV infections and incident T. vaginalis infections 
(Hazard Ratio: 1.60, 95% Confidence Interval: 1.00, 2.57, p=0.04).  
 
1.1.1 History  
The observation and description of the protozoan T. vaginalis was first made in the year 1836 
by Alfred Donné, a French physician (Powell, 1936). T. vaginalis was identified as a motile 
microorganism present in women who had shown signs of leukorrhea (vaginal discharge which 
appears to be thick, whitish or yellowish in colour as well as irritation in the genital area) (Harp 
and Chowdhury, 2011). During the period 1934-1939, an Italian scientist, Procaccini classified 
and identified the morphological characteristics of T. vaginalis. Procaccini identified T. 
vaginalis as being a sexually transmitted disease amongst a group of Italian soldiers who served 
in the Italian army in Ethiopia. Currently, various studies are being conducted involving 
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molecular biology and immunologic methods to better understand the pathogenesis of T. 
vaginalis (Harp and Chowdhury, 2011). 
1.1.2 Morphology of T. vaginalis 
Trichomonas vaginalis is known to be one of the most well studied parasites amongst all 
trichomonads. It is single- celled and oval or pear shaped, i.e. pyriform or amoeboid as shown 
in Figure 2C (Petrin et al., 1998; Harp and Chowdhury, 2011). However, both the shape and 
size can differ with the average width and length being 7 µm and 10 µm, respectively (Petrin 
et al., 1998; Harp and Chowdhury, 2011). Physiochemical conditions can lead to changes in 
the appearance of the parasite. T. vaginalis is a flagellated protozoan having five flagella, four 
located within the anterior portion whereas the fifth flagellum is integrated within the 
undulating membrane originating from the blepharoplasty of the parasite as shown in Figure 
2A (Petrin et al., 1998; Harp and Chowdhury, 2011). 
The cytoskeleton found in the parasite T. vaginalis is made up of both actin fibres and tubulins. 
Researchers have established the presence of different types of tubulin inside a trichomonad 
cell (Petrin et al., 1998). The actin isolates of T. vaginalis are known to migrate slower in 
comparison to actin isolates from muscles. The location of the nucleus is situated in an anterior 
portion which is enclosed by a porous nuclear envelope. Another structure found on the parasite 
T. vaginalis is an axostyle which is a small hyaline, rod-like structure. This specific structure 
overhangs through the posterior end of the parasite enabling the parasite to anchor to the 
epithelial cells of the vagina resulting in inflammation as shown in Figure 2B (Petrin et al., 














Figure 2: (A) Presence of protozoan T. vaginalis in broth culture. The image clearly shows the 
visibility of the flagella, axostyle and undulating membrane. (B) Protozoan T. vaginalis on the 
surface of a vaginal epithelial cell before amoeboid transformation. (C) T. vaginalis amoeboid 
morphology presence in cell culture. Bars- 5 mm (Petrin et al., 1998). 
1.1.3 Transmission and life cycle 
The life cycle of T. vaginalis involves asexual replication via binary fission and mitotic division 
in humans as the host (Figure 3). This particular parasite colonizes the lower genital tract of 
women whereas in men it is present in the urethra and prostate (Simon, 2018). T. vaginalis 
does not have a cyst, therefore the flagellate will not be able to survive outside the human body. 
A moist environment is essential in order for transmission to take place. Sexual transmission 
is regarded as being the main manner of transmission, even though non-sexual transmission 
has been reported in previous studies (Crucitti et al., 2011). For example, newborn infants can 









parasite enters into the vaginal tract during delivery causing the birth canal to become infected.  
This results in infants having urinary tract infections, vaginitis and even upper respiratory 
distress (Danesh et al., 1995).  
 
 
Figure 3: Illustrates both the life cycle and transmission of T. vaginalis present in males and 
females. (1) Presence of the protozoan in the lower genital tract in a female and the prostate 
and urethra in a male. (2) Replication via binary fission. (3) Transmitted amongst humans via 
sexual intercourse (Ramos, 2005). 
 
1.1.4 Clinical manifestation and Pathogenesis  
There are a number of mechanisms that are involved in the pathogenesis of T. vaginalis, such 
as hemolysis, secretion of soluble factors, and cell-to-cell adhesion, which eventually leads to 
inflammation and damage to epithelial cells (Gilbert et al., 2000). T. vaginalis is considered as 
being a free-living protozoan capable of colonizing the surfaces of mucosal epithelial cells. In 
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males infected with T. vaginalis, the parasite normally persists between 2 weeks to 4 months 
in the prostrate or urethra (Simon, 2018), whereas in infected females, the parasite can persist 
up to approximately 5 years in the genital tract (Simon, 2018).  
This pathogen has also been detected in individuals who are asymptomatic, hence showing no 
symptoms of trichomoniasis. Men with trichomoniasis may display the following symptoms; 
burning sensation during urination or sexual intercourse, discharge from the penis and itching 
of the penis (Centres for Disease Control (CDC), 2012).  Health associated complication in 
males infected with T. vaginalis includes infertility, prostatitis, increased risk of prostate cancer 
and non-gonococcal urethritis (Conrad et al., 2012).  
Women infected with trichomoniasis display symptoms including; abnormal vaginal odour 
(“musty” or ‘’fishy” vaginal smell), pruritus, lower abdominal pain, purulent vaginal discharge 
(discharge which is thick and milky white, greenish or yellowish), punctate microhemorrhages 
referred to as ‘strawberry cervix’ as well as dyspareunia (genital pain during, before or after 
sexual intercourse) (Bowden et al., 2000; Harp and Chowdhury, 2011; Conrad et al., 2012). 
Studies have shown that approximately 20% of the women who have trichomoniasis infection 
often develop a foul odour and a foamy discharge (Lehker and Alderete, 2000; Ribeiro et al., 
2003; Lima et al., 2013). 
 The associated health consequence for women being infected with trichomoniasis, include 
infertility (Tsevat et al., 2017). Generally, women infected with trichomoniasis have a much 
higher risk of having pelvic inflammatory associated diseases compared to women who are 
uninfected (Moodley et al., 2002).  
For pregnant women some of the adverse outcomes of a T. vaginalis infection includes having 
a low-birth weight infant and preterm delivery (Kamal et al., 2018).  In a study conducted in 
HIV infected pregnant women from Zimbabwe it was reported that vaginal infections which 
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includes T. vaginalis are critical predictors for vertical transmission of HIV (Gumbo et al., 
2010).   
1.1.5 Treatment of T. vaginalis infections 
Individuals infected with T. vaginalis are commonly treated with a drug referred to as 
metronidazole (Mz). This drug is a 5-nitroimidazole (C3H3N3O2) drug derived from the 
Streptomyces producing antibiotic azomycin. Studies have shown that metronidazole is highly 
effective for the treatment of trichomoniasis (Petrin et al., 1998).  T. vaginalis is transmitted 
mostly sexually, therefore respective partners will also need to be treated.  
A metronidazole vaginal gel has also been tested, however, studies have shown that the gel is 
effective in only approximately half of the reported trichomoniasis cases (Cudmore et al., 
2004). A study was conducted which compared the treatment for trichomoniasis with vaginal 
tablets with a low dosage of metronidazole (100 mg) and oral metronidazole (500 mg twice a 
day) for 7 days. The study showed that treatment with vaginal tablets containing 100 mg of 
metronidazole resulted in a 64% cure rate (Bouckaert et al., 1995; Voorspoels et al., 2002; 
Bouchemal et al., 2017).  
There have been reports on the emergence of metronidazole resistant T. vaginalis (Coelho, 
1997; Nyirjesy et al., 1998). 
A study conducted by Coelho, 1997 reported on a patient who had a trichomoniasis infection 
with treatment failure to high doses of metronidazole. In another study involving nine patients 
who were infected with trichomoniasis, four of the nine patients had T. vaginalis strains which 





1.2 Laboratory diagnosis of T. vaginalis 
1.2.1 Microscopy  
Microscopy (wet-mount preparation) still remains a traditional method for the identification of 
trichomoniasis. Samples are typically obtained from prostatic secretions, urethral secretions 
and cervical or vaginal samples which are then used to observe motile forms of this particular 
protozoa, hence flagella movement (Garber, 2005). However, it is important to note that the 
sensitivity of microscopy ranges from approximately 38% to 82%.  
Accurate analysis with microscopy is dependent on a number of factors such as the size of the 
inoculum, quality of the sample and the observer’s experience (Garber, 2005). Non-motile 
trichomonads are difficult to distinguish from vaginal epithelial cell nuclei. Despite the low 
cost of this technique, the low levels of sensitivity could lead to a misdiagnosis of T. vaginalis 
(Garber, 2005).  
1.2.2 Culture  
Over the past 40 years the broth culture technique has been recognized has being the “gold 
standard’’ for T vaginalis identification. The size of the inoculum needed for an easy diagnosis 
is approximately 300 to 500 trichomonads /mL (Petrin et al., 1998; Garber, 2005). Diamond’s 
TYI medium is the media of choice for culture. For the identification of T. vaginalis in culture 
an incubation period of between two to seven days is required (Garber, 2005).  
A possible limitation with culture is that broth tubes can become easily contaminated with 
bacteria. However, this can be eliminated by adding antibiotics into the broth to inhibit the 
growth of the bacteria (Garber, 2005). 
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 In order to improve the adequacy of culture for diagnosis, the development of a plastic 
envelope technique was established. This self-contained system involves instant examination 
and culturing. The results obtained from such a system is in fact equivalent to the culture 
techniques and wet-mount preparation (Petrin et al., 1998, Garber, 2005). 
1.2.3 Staining  
The use of staining techniques was introduced to increase the sensitivity of microscopy (Petrin 
et al., 1998). The types of stains used include; periodic acid Schiff, acridine orange and Fontana 
and Leishman. Papanicolaou (Pap) staining is popular for trichomoniasis diagnosis, since it is 
often used in gynaecologic screening to detect cytological abnormalities amongst individuals 
who have high prevalence rates of STIs.  However, a limitation with staining techniques is loss 
of morphology of T. vaginalis as a result of fixation before staining (Petrin et al., 1998). 
1.2.4 Antibody- Based Techniques  
Eight serotypes have been detected in T. vaginalis, with the use of immuno-blot analysis, 
(Garber, 2005). The presence of anti-trichomonal antibodies can be determined via the use of 
the following techniques; enzyme-linked immunosorbent assay (ELISA), complement fixation, 
agglutination, indirect hemagglutination, fluorescent antibody and gel diffusion (Petrin et al., 
1998; Garber, 2005).  
 The use of monoclonal antibodies can be a promising way of detecting T. vaginalis antigens 
from clinical samples to diagnose trichomoniasis. In a study conducted by Krieger et al., 1985 
two reactive monoclonal antibodies were able to identify 88 strains of T. vaginalis from North 
American regions.  Monoclonal antibodies which were used for the detection of T. vaginalis 
from clinical samples gave similar results to those obtained by wet-mount preparations 
(Garber, 2005).  
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1.2.5 DNA- Based Techniques  
The diagnosis of T. vaginalis using recombinant DNA techniques are often used in clinical 
laboratories due to improved sensitivity and specificity. DNA based assays such as the BD 
Affirm VPIII assay, TaqMan based assay and the BD Max ™ Vaginal Panel assay are 
commercially available assays for the detection of T. vaginalis (Dessai et al., 2020; Mabaso et 
al., 2020). These highly sensitive assays make use of synthetic oligonucleotide probes for 
detecting T. vaginalis from vaginal swabs (Dessai et al., 2020; Mabaso et al., 2020). Dot-blot 
hybridization is another technique which can be used for the detection of T. vaginalis. This 
technique makes use of a 2.3-kb T. vaginalis DNA fragment which acts as a probe and is 
capable of detecting T. vaginalis DNA from vaginal extracts (Petrin et al., 1998; Garber, 2005). 
However, this technique involves the handling of radioactive material, thereby posing a 
limitation. An alternative technique is in situ hybridization which uses a 2.3-kb fluorescence-
labelled DNA probe for identifying T. vaginalis (Petrin et al., 1998; Garber, 2005). 
1.3 Genotyping of T. vaginalis 
Many molecular based techniques have been used in the past in order to distinguish T. vaginalis 
strains. These techniques include; Microsatellite genotyping, Multilocus Sequence 
Typing (MLST), Polymerase Chain Reaction (PCR) based-hybridization, Random 
Amplification of Polymorphic DNA (RAPD), PCR-size polymorphism and PCR-Restriction 
Fragment Length Polymorphism (PCR-RFLP) (Khalili et al., 2017).  
1.3.1 Microsatellite genotyping 
Microsatellites refer to short sequences of nucleotides arranged in tandem repeats with the 
length generally consisting of two to six base pairs (Conrad et al., 2011). Microsatellite 
genotyping has been considered as an appropriate tool for investigating the diversity of T. 
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vaginalis (Meade and Carlton, 2003). In order to understand the genetic diversity of T. 
vaginalis, a panel of 21 microsatellites and six single copy genes from the T. vaginalis genome 
were recognized and validated. The diversity assessments were conducted in seven laboratory 
strains of T. vaginalis (Conrad et al., 2011). 
1.3.2 Multilocus Sequence typing (MLST) 
Multilocus Sequence typing (MLST) differentiates isolates by making use of internal sequence 
fragments of about seven housekeeping genes. The genes are amplified by PCR and then 
sequenced to identify specific alleles (Maiden, 2006; Cornelius et al., 2012) (Figure 4).  
Cornelius et al., 2012, conducted a study among 68 T. vaginalis isolates. The results obtained 
with MLST showed the identification of 43 polymorphic nucleotide sites, 51 different alleles 
as well as 60 sequence types. Van der Veer et al., 2016 performed a diversity assessment study 
on stored samples of men and women who tested positive for T. vaginalis. The study results 
revealed that 7 loci were positively typed using MLST in 81.6% (71/87) of the samples 
analysed. Samples were separated into genotypes I and II representing the T. vaginalis structure 




Figure 4: Outline of the MLST procedure. Different gene targets are amplified by making use 
of the locus-specific primers (represented by the smaller arrows). The genes are sequenced 
after PCR amplification. The DNA sequences are then matched with other sequences from the 
MLST database, assigning a name for the allele. The assigned alleles for every locus are then 
joint resulting in the formation of a Multilocus Sequence type (Singh et al., 2006).   
1.3.3 Random Amplification of Polymorphic DNA (RAPD) 
Random Amplification of Polymorphic DNA (RAPD) genotyping consists of randomly 
amplifying segments of the target DNA making use of a single primer, which does not show 
homology to a specific target DNA sequence (Swaminathan and Matar, 1993; Naidoo, 2015).  
Merdaw et al., 2014 conducted a study which used four random primers i.e. OPD1, OPD2, 
OPD3, and OPD5 in order to determine the genotypic difference amongst T. vaginalis isolates 
obtained from women with and without cervical abnormalities. The results obtained indicated 
that primers OPD2, OPD3 and OPD5 showed polymorphic bands, whereas primer OPD1 
showed no fragment amplification in any of the isolates analysed.  This technique can be 
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compromised by variations in experimental PCR conditions and the presence of contaminating 
DNA (Meade and Carlton, 2003).  
 
Figure 5: Illustrates the RAPD procedure. Amplification results in multi-fragment PCR 
patterns, allowing for the screening of polymorphisms in a number of regions in the genome 
due to the DNA sequence variation at or between the primer-binding sites (Pasqualone, 2013).   
1.3.4 PCR– Restriction Fragment Length Polymorphism (PCR-RFLP) 
Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP) 
involves the amplification of a known DNA sequence, followed by restriction of the resulting 
amplicons by means of restriction endonuclease enzymes.  Gel electrophoresis is then used to 
determine the differences in the restricted DNA fragment sizes by analysis of banding profiles 
(Swaminathan and Matar, 1993; Naidoo, 2015).  
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Genotyping of T. vaginalis by PCR-RFLP has been performed by using primers targeting the 
intergenic spacer (IGS) region of the ribosomal DNA (Simoes-Barbosa et al., 2005; Kock et 
al., 2013). A study conducted on 60 clinical isolates of T. vaginalis, digested with eight 
restriction enzymes using IGS-PCR RFLP, showed no genetic variation between isolates 
(Simoes-Barbosa et al., 2005).  Similarly, a study performed by Kock et al., 2013 in South 
Africa showed no genetic differences amongst 92 clinical isolates of T. vaginalis by IGS-PCR 
RFLP. However, genetic differences were observed in those same isolates by the RAPD 
technique (Kock et al., 2013). It was therefore suggested that the differentiate capability of 
PCR-RFLP is dependent specifically on the region that is targeted in the genome. 
Crucitti et al., 2008 identified different genotypes of T. vaginalis based on the digestion of the 
actin gene. The study identified eight T. vaginalis actin genotypes amongst 151 isolates 
obtained from the Democratic Republic of Congo and Zambia. Another study conducted in 
Africa identified distinct genotypes of T. vaginalis based on digestion of the actin gene (Masha 
et al., 2017). Studies conducted in Iran, had also reported on the successful assignment of T. 
vaginalis genotypes based on the actin gene (Matini et al., 2017; Khalili et al., 2017; Oliaee et 
al., 2017).   
1.4 Rationale 
Currently, there is a lack of data on the circulating genotypes of T. vaginalis in South African 
populations, particularly pregnant women. In the present study, Polymerase Chain Reaction-
Restriction Fragment Length Polymorphism (PCR-RFLP) of the actin gene was performed in 
order to identify the different genotypes of T. vaginalis. This study provided a snapshot into 
the molecular epidemiology of T. vaginalis in our region which can be used as a foundation for 





Due to the relatively high prevalence of T. vaginalis in our setting, we hypothesize that a 
distribution of different genotypes will be present in our study population.  
1.6 Aims and objectives 
 
AIM:  
The aim of this study was to determine the different genotypes of T. vaginalis present in 
pregnant women from Durban using restriction fragment length analysis. 
OBJECTIVES:  
1. To detect the presence of T. vaginalis by the Polymerase Chain reaction using DNA 
extracted from vaginal swabs; 
2. To determine the genotypes of T. vaginalis that are present in this population by restriction 
fragment length analysis of the actin gene; and 
3. To link the different genotypes with the clinical data (i.e. symptoms associated with vaginal 
infections) obtained from the study population.  
1.7 Outputs 
The Research Article titled "Genotypic variation in Trichomonas vaginalis detected in South 
African pregnant women," by Rennisha Chetty, Nonkululeko Mabaso and Nathlee S. Abbai 
has been received and assigned the number 1687427. 






METHODS AND MATERIALS 
 
3.1 Ethics Statement 
The current study was approved by the Biomedical Research Ethics Committee (BREC) of the 
University of KwaZulu-Natal (BREC/00000406/2019) (Appendix I). 
3.2 Study design and population 
The current study was a retrospective laboratory based study making use of stored DNA 
extracted from vaginal swabs collected from pregnant women. The swabs were collected 
through a larger study which was conducted from October 2018-April 2019 (Appendix II).  For 
the larger study, n=362 pregnant women were recruited from the King Edward VIII hospital 
antenatal clinic in Durban. The women were 18 years and older and willing to provide written 
informed consent and two self-collected vaginal swabs. At enrolment, all women also provided 
data on their socio-demographic statuses (age, marital status, level of education), sexual 
behaviour (age of first sex, cohabitation status, condom use and number of life-time sexual 
partners) and clinical history (trimester of pregnancy, history of STIs, previous pregnancy 
history). The data was collected using a structured questionnaire.  For this study, de-linked 
DNA samples were analysed. The parent study contained 362 DNA samples and all these 
samples were retrieved for analysis in this study.        
3.3 Processing and storage of samples from the larger study 
Upon collection, one swab was placed immediately in Diamonds media for T. vaginalis culture. 
The second swab (dry swab) was placed in a sterile tube for molecular analysis. The samples 
were transported at room temperature to the School of Clinical Medicine’s Research 
Laboratory at the Nelson R. Mandela School of Medicine, University of KwaZulu-Natal. The 
dry swabs were then re-suspended in 2ml of phosphate buffered saline (PBS) and vortexed to 
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remove the sample material from the swab.  After vortexing the swab was discarded and the 
PBS solution containing the vaginal material was subjected to DNA extraction. For the 
extraction, the entire 2ml of PBS was used and the DNA was extracted using the PureLink 
Microbiome DNA Purification Kit (Invitrogen, supplied by ThermoFisher Scientific, United 
States) according to the manufacturer’s instructions. The concentration and purity of the 
extracted DNA was assessed using the Nanodrop spectrophotometer (ThermoFisher Scientific, 
United States) prior to storage at -20C.  
3.4 Laboratory procedures 
3.4.1 Sample retrieval  
The full set of n=362 DNA samples were available for analysis in the current study. All 
demographic, behavioural and clinical data linked to the stored samples were also available for 
analysis in this study.  
3.4.2 Detection of T. vaginalis from stored DNA extracted from vaginal 
swabs  
A total of n=362 vaginal swab DNA samples were tested for the presence of T. vaginalis.           
T. vaginalis was detected using the Applied BiosystemsTM TaqMan® Assays. Commercial 
primers and probes (Pr04646256_s1) which target the alpha tubulin 1 gene of T. vaginalis were 
used. Amplification was performed on the Quant Studio 5 Real-time PCR detection system 
(ThermoFisher Scientific, United States).  
Briefly, each reaction was performed in a final volume of 5 µL which comprised of: 0.5 µL 
FAM-labelled probe/primer mix, 2.5 µL Fast Start 4x probe master mix (ThermoFisher, 
Pr04646256_s1), 1.5 µL template DNA and nuclease-free water.  We also included non-
template control reactions.  Amplification was performed under the following conditions: 1 
cycle at 95C for 30 seconds followed by 45 cycles of denaturation at 95C for 3 seconds and 
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annealing at 60C for 30 seconds. Detection of fluorescent products was performed at the end 
of the annealing period. The raw fluorescent data that included the CT mean values and gene 
copy numbers, were automatically generated by the Quant Studio 5 Real-time PCR system 
software.  
3.5 Detection of the actin genes from T. vaginalis  
A conventional nested PCR assay was used for the amplification of the actin genes (outer and 
inner regions) using oligonucleotide primers, published by Espinosa et al., 2001 and Khalili et 
al., 2017. The primers used for amplification of inner and outer actin genes are shown in Table 
1.  
Table 1: Description of primers used for the amplification of the actin genes in the studied 
population. 
Primer name  Primer sequence  
Outer actin Forward (Tv8S) 5’-TCTGGAATGGCTGAAGAAGACG-3’ 
Outer actin Reverse (Tv9R) 5’-CAGGGTACATCGTATTGGTC-3’ 
Inner actin Forward (Tv10S) 5’-CAGACACTCGTTATCG-3’ 
Inner actin Reverse (Tv11R) 5’-CGGTGAACGATGGATG-3’ 
 
3.6 Amplification of the outer actin gene  
The amplification reactions were performed with a total volume of 25 µl. The reaction 
contained 12.5 µl Dream Taq master mix (ThermoFisher Scientific, United States), 9.5 µl 
distilled water, 0.5 µl of each primer (reverse and forward) and 2 µl of the template DNA. The 
negative control contained 23 µl of PCR mixture and 2 µl of distilled water. Thereafter, the 
PCR tubes were placed into the thermal cycler and the following cycling conditions were 
performed; initial denaturation at 94°C for 5 minutes, followed by 30 cycles each consisting 
of: denaturation at 94°C for 1 minute, annealing 54°C for 1 minute, elongation 72°C for 1 
minute and final elongation at 72°C for 5 minutes.  
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3.7 Amplification of the inner actin gene by nested PCR 
The nested amplification reactions were performed in PCR with a total volume of 25 µl. The 
reaction contained 12.5 µl Dream Taq master mix, 9.5 µl distilled water, 0.5 µl of each primer 
(reverse and forward) and 2 µl of the outer PCR product. The negative control contained 23 µl 
of PCR mixture and 2 µl of distilled water. Thereafter, the PCR tubes was placed into the 
thermal cycler and the following conditions were performed; initial denaturation at 94°C for 5 
minutes, thereafter 30 cycles of; denaturation at 94°C for 1 minute, annealing at 45°C for 1 
minute, elongation at 72°C for 1 minute and a final elongation at 72°C for 5 minutes.  
3.8 Visualization of the PCR amplicons  
Agarose gel electrophoresis was performed in order to confirm if the PCR amplification was 
successful. PCR products were loaded onto a 1% agarose gel which was stained with 4 µl of 
SYBR safe dye (ThermoFisher Scientific, United States). Each well was loaded with 5 µl of 
loading dye and 10 µl of the PCR product and was run at a voltage of 100 for 45 minutes, and 
then viewed using an ultraviolet trans-illuminator (Gene Genius, SYNGENE, United States). 
The molecular weight marker used for identifying the presence of the bands was the Gene-
Ruler 100 bp Plus DNA Ladder, ready-to-use (Catalogue number:  SM0323). 
3.9 Sequence confirmation of the inner actin gene 
A subset comprising of 10 PCR positive amplicons, i.e. TV184, TV211, TV230, TV232, 
TV253, TV266, TV270, TV302, TV357, TV358 were sequenced to confirm the presence of 
the gene prior to the genotyping analysis.  
Sanger DNA sequencing was performed on the inner actin PCR amplicons. Each amplicon was 
sequenced in both directions to cover the full length actin gene.  The sequencing was conducted 
using the BrilliantDye™ Terminator v3.1 Cycle Sequencing on an ABI3500XL genetic 
24 
 
analyser. The sequencing was performed at Inqaba Biotechnical Industries (Hatfield, Pretoria, 
South Africa). The ABI sequencing files were edited on CHROMAS (Technelysium, 
Queensland, Australia). The forward and reverse sequences were aligned using the DNAMAN 
software (Lynnon Biosoft, California, United States). The identity of the edited sequences was 
confirmed using the National Center for Biotechnology Information (NCBI) Basic Local 
Alignment Search Tool (BLAST). 
3.10 Restriction Fragment Length Polymorphisms (RFLP)  
The genotyping of the actin gene was performed using the RFLP technique. Restriction 
enzymes, HindII, MseI, and RsaI were used to generate the banding profiles. The inner actin 
amplicons were digested with the individual enzymes. The digestion mix was made up to a 
final volume of 20 µl. Each reaction consisted of 0.5 µl enzyme, 2 µl enzyme buffer, 0.2 µl 
bovine serum albumin (BSA), 7.3 µl distilled water and 10 µl of the PCR product.  The 
digestion reactions were incubated for 4 hours under the following temperature conditions  
37° C for both MseI and RsaI enzymes, and 64°C for the HindII restriction enzyme (Khalili et 
al., 2017).  
Following incubation, the digests were run on a 2% agarose gel which was stained with 4 µl of 
SYBR safe dye (ThermoFisher Scientific, United States). Each well was then loaded with 5 µl 
of loading dye and 20 µl of the digestion mix. The gels were electrophoresed at 80 volts for 2 
hours. The enzymes banding patterns and assignment of genotypes based on a composite of 
the patterns was determined according to Khalili et al., 2017. The molecular weight marker 
used for identifying the presence of the bands for restriction enzyme MseI was the Gene-Ruler 
100 bp Plus DNA Ladder, ready-to-use (Catalogue number:  SM0323). Whereas for restriction 
enzymes RsaI and HindII Gene-Ruler 50 bp DNA Ladder, ready-to-use (Catalogue 
number:  SM0373) was used.  
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3.11 Phylogenetic Analysis of actin genotypes   
Selected samples harbouring different genotypes for the actin gene after digestion with the 3 
enzymes were selected for further phylogenetic analysis. The amplicons were sequenced in 
both directions using the Sanger approach. The sequencing was performed on an ABI3500XL 
genetic analyser at Inqaba Biotechnical Industries (Hatfield, Pretoria, South Africa).  The ABI 
sequencing files were edited on CHROMAS (Technelysium, Queensland, Australia). The 
forward and reverse sequences were aligned using the DNAMAN software (Lynnon Biosoft, 
California, United States). The DNA sequences were translated to protein using the freely 
available software ExPASy (https://web.expasy.org/translate/).  The translated sequences 
together with published Actin protein sequences were aligned using Clustal W 
(https://www.genome.jp/tools-bin/clustalw). The alignments were performed in order to 
identify amino acid substitutions. A phylogenetic tree was then constructed from the sequence 
data using the Molecular Evolutionary Genetics Analysis (MEGA) version 10 software 
(Arizona, United States). 
3.12 Statistical Analysis 
Frequency distribution and percentages was used to describe both the demographic and clinical 

















4.1 Detection of T. vaginalis from DNA extracted from vaginal swabs 
The presence of the alpha tubulin 1 gene was detected in 47/362 (12.98%) swab DNA samples 
by the real-time PCR TaqMan assay. The quantification cycle (Cq) for the samples that 
produced positive amplification ranged from 25-35 cycles. All negative no template controls 
did not produce any amplification. Positive amplification was shown as the curves above the 
baseline threshold (indicated as a straight red line) (Figure 6). 
 
Figure 6: Graph of the amplification plots showing the fluorescent signal from each sample is 
plotted against cycle number; therefore, representing the accumulation of product over the 
duration of the real-time PCR experiment. Positive amplification is shown as the curves above 




4.2 Baseline characteristics of the women from the parent study 
There was a total of 362 pregnant women were screened for T. vaginalis (TV) infection. The 
characteristics of these women according to T. vaginalis infection status is summarized in 
Table 2. A total of 47/362 (13%) women tested positive for T. vaginalis infection. A total of 
59.6% of the women who tested positive for T. vaginalis in this study, did not complain of 
current abnormal discharge, i.e. were asymptomatic.  
Socio- Demographics Status 
The baseline characteristics stratified by infection status is summarized in Table 2. For the 
women who tested T. vaginalis positive, majority of them fell in the age groups 20-25 (38.3) 
and above 30 (38.3). However, age was not significantly associated with infection (p = 0.172). 
There was also no statistical significance with regards to the level of education and employment 
status (p = 0.580; and p = 0.332, respectively) for the T. vaginalis positive women.  
Behavioural factors  
There was high prevalence of T. vaginalis infection among pregnant women who were not 
married (91.5%), who had a regular sexual partner (80.9%), who were not living with their 
partner (57.4%), who had their first sexual encounter between the age of 15 to 20 (70.2%), who 
had between 2 to 4 life-time sexual partners (66%), who did not know if their partners had 
other partners (61.7%), and those who reported that they sometimes use condoms (76.6%). 






Clinical data  
Women who were in their third trimester of pregnancy and those who reported no STI 
symptoms (abnormal vaginal discharge, abnormal vaginal odour and genital itching or sores or 
warts) in the past three months had a high prevalence of T. vaginalis infection (59.6% and 
57.4%, respectively), However, these factors were not statistically significant (p > 0.05) as 
indicated in Table 2. There was high prevalence of T. vaginalis infection in women that were 
asymptomatic (no abnormal vaginal discharge at the time of the study enrollment), 
(prevalence=59.6%, p = 0.011).  
Table 2: Baseline characteristics of the study population according to T. vaginalis infection 
status. 





Age   0.172 
15-20 7.9% 4.3%  
21-25 24.4% 38.3%  
26-30 28.3% 19.1%  
>30 39.4% 38.3%  
Education Level   0.580 
College, University 26.3% 27.7%  
Didn’t attend school 1.9% 0.0%  
High school 69.8% 68.1%  
Primary school 1.9% 4.3%  
Employment   0.332 
No 70.8% 63.8%  
Yes 29.2% 36.2%  




No 87.9% 91.5%  
Yes 12.1% 8.5%  
Regular sexual partner   0.531 
No 15.6% 19.1%  
Yes 84.4% 80.9%  
Co-habiting   0.677 
No 60.6% 57.4%  
Yes 39.4% 42.6%  
Age at first sex   0.589 
<15 1.3% 0.0%  
15-20 75.2% 70.2%  
21-25 20.3% 27.7%  
>25 3.2% 2.1%  
Lifetime sex partners   0.365 
1 23.8% 23.4%  
2-4 61.3% 66.0%  
>4 14.9% 10.6%  
Partner has other partners   0.406 
Don't know 56.8% 61.7%  
No 23.5% 14.9%  
Yes 19.7% 23.4%  
Condom use   0.646 
Always 0.6% 0.0%  
Never 29.2% 21.3%  
Rarely 1.6% 2.1%  
Sometimes 68.6% 76.6%  
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Trimester of pregnancy   0.608 
1st 13.7% 12.8%  
2nd 34.3% 27.7%  
3rd 52.1% 59.6%  
Current Abnormal Vaginal 
Discharge 
  0.011 
No 76.8% 59.6%  
Yes 23.2% 40.4%  
Previous STI treatment   0.558 
No 76.8% 59.6%  
Yes 23.2% 40.4%  
STI symptoms in the past 3 
months 
  0.488 
Abnormal Vaginal Discharge 36.2% 34.0%  
Genital itching/sores 14.0% 8.5%  
None 49.8% 57.4%  
 
4.3 Past clinical symptoms associated with the prevalence of T. vaginalis in 
the antenatal women 
 
For the larger study, the women also provided data on symptoms of vaginal infections 
experienced in the 3 months prior to enrolment in the study (Figure 7). Table 3, illustrates the 
percentages of single and combined symptoms experienced. Despite testing positive for T. 
vaginalis in the current study, 57.4% of the women had reported that they had not experienced 
any past symptoms associated with infection. Abnormal vaginal discharge and genital itching 
were the most common symptoms experienced in the past (8.5%, respectively). A less common 
symptom reported was foul smelling vaginal odour (2.1%). Approximately, 6.4% of the women 
had experienced combined symptoms of abnormal vaginal discharge; genital itching and 
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vaginal odour. Combined symptoms of abnormal vaginal discharge and vaginal odour (2.1%); 
abnormal vaginal discharge and genital itching (4.2%); abnormal vaginal discharge, genital 
itching, vaginal odour, genital ulcers/sores, genital warts (2.1%) were also reported (Table 4).  
 
Figure 7: Past number of clinical symptoms associated with vaginal infections reported by the 
study population (n=362) in the larger study studied. 
 
Table 3: Clinical symptoms displayed by the number of infected women with percentages 
observed.  




No symptoms 208 57.4 
AVD 30 8.5 
VO 8 2.1 
GI 30 8.5 
AVD + VO 8 2.1 
AVD +GI 15 4.2 
VO + GI 8 2.1 
AVD + GI + VO 23 6.4 
AVD + GI + S/U 8 2.1 
AVD + VO + GI + GW 15 4.2 
AVD + VO + GI + GW + S/U 8 2.1 
No data proved 1 0.3 
 
KEYS: AVD- Abnormal vaginal discharge, GI - Genital Itching, VO- Vaginal Odour, GW- 
Genital Warts, S/U- Sores/Ulcer 
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4.4 Results of the amplification reactions  
4.4.1 Amplification of the outer actin gene of T. vaginalis  
Amplification of the outer actin gene by conventional PCR yielded 16 positives out of the 47 
samples tested.  The majority of the samples (23/31) that did not test positive in the initial PCR 
showed either low DNA concentration or purity ratios (Appendix II). For the low concentration 
samples, the reactions were repeated with an increased amount of DNA, however, the 
adjustment still did not result in successful amplification of the outer actin gene. For lower 
purity samples, the suggestion of potential sample inhibitors that could have negatively affected 
the PCR reaction was not found to hold true, since the samples were amplifiable for other genes 
such as the Mycoplasma hominis 16S rRNA that were not part of this study (data not shown). 
For the 16 samples that produced a positive amplicon the expected fragment size of 1300bp 
was observed after agarose gel electrophoresis (Figure 8). No amplification was noted for the 
no template control (negative control- lane 2, Figure 8). A sub-set of 10 samples is shown in 












Figure 8: Agarose gel showing positive amplicons generated for the outer actin gene. The 
expected fragment size of 1300bp was observed. M: 100bp DNA molecular ladder 
(ThermoFisher Scientific), NC: negative control (no template DNA added) and Lane 3-12: 
clinical samples amplified clinical samples.  
4.4.2 Amplification of the inner actin gene of T. vaginalis by nested PCR 
The 16 positive amplicons generated for the outer actin gene were used as a template for the 
PCR reactions to amplify the inner actin gene. The inner actin gene was amplified in all 16 
samples. The expected fragment size of 1100bp was observed after agarose gel electrophoresis 
(Figure 9). The fragments were of a good quality (single band of high intensity) for further 


















































































Figure 9: Agarose gel showing positive amplicons generated for the inner actin gene. The 
expected fragment size of 1100bp was observed. M: 100bp DNA molecular ladder 
(ThermoFisher Scientific), NC: negative control (no template DNA added) and Amplified 
clinical samples. A product size of 1100bp indicative of the inner actin gene was present in all 






4.5 Sequence confirmation of the actin gene prior to genotyping analysis 
Sanger sequencing confirmed that the amplicons generated with the actin primers were the 
actin gene from T. vaginalis. The DNA sequencing hits of the actin gene showed identity 
(99%) to T. vaginalis isolate 19 actin gene (MF350343.1) and T. vaginalis strain ATCC 30240 
actin gene (99%) (EU076579.1) (Table 4). 
Table 4: DNA sequencing hits according to NCBI BLAST confirming the presence of the actin 
gene amplified from clinical isolates testing positive for T. vaginalis. 
Query sample BLAST HIT % Identity Accession number 
TV184 Trichomonas 
vaginalis isolate 19 
actin gene, partial cds 
99% MF350343.1 
TV211 Trichomonas 
vaginalis isolate 19 
actin gene, partial cds 
99% MF350343.1 
TV230 Trichomonas 
vaginalis isolate 19 
actin gene, partial cds 
99% MF350343.1 
TV232 Trichomonas 
vaginalis isolate 19 
actin gene, partial cds 
98% MF350343.1 
TV253 Trichomonas 
vaginalis isolate 19 
actin gene, partial cds 
98% MF350343.1 
TV266 Trichomonas 
vaginalis isolate 16 
actin gene, partial cds 
98 MF350337.1 
TV270 Trichomonas 
vaginalis isolate 19 
actin gene, partial cds 
98% MF350343.1 
TV302 Trichomonas 
vaginalis isolate 19 
actin gene, partial cds 
99% MF350343.1 




vaginalis isolate 19 




ATCC 30240 actin 




4.6 Genotyping analysis  
 
4.6.1 HindII profile  
All samples produced a banding pattern for HindII. A consistent banding profile was observed 
across all samples (Figure 10). Numerous bands were observed for this digest which had not 
been previously published (Khalili et al., 2017). Since all the samples produced the same 
banding profile, one sample (TV266) was selected (based on having a bright banding pattern, 
Figure 10) for analysis using the freely available Restriction mapper tool 
((http://www.restrictionmapper.org/cgi-bin/sitefind3.pl). According to Restriction mapper, only 
four fragments should have been yielded at positions, 60bp, 200bp, 386bp and 426bp (Table 
5). These four fragments were shown to be present on the gel (Figure 10). The additional bands 
observed could have been due to star activity by the enzyme (i.e. cutting at non-specific 
recognition sites due to prolonged incubation period or too high enzyme concentration). Based 
on the identical banding pattern across all samples, the samples were assigned the same pattern 


















Figure 10: HindII RFLP pattern of the digested actin gene amplicon resolved on a 1.5% 
agarose gel. M: O’GeneRuler 50bp DNA Ladder (ThermoFisher Scientific) and banding 
profiles of the clinical samples. Size fragments of 60bp, 200bp, 386bp and 426bp were 





















































Table 5: Virtual digest of sample TV266 with the Restriction Mapper tool. 
(http://www.restrictionmapper.org/cgi-bin/sitefind3.pl) 
 
4.6.2 RsaI profile  
All samples produced banding patterns for RsaI. Three different banding patterns were 
observed for RsaI (Figure 11). Of the 16 samples digested, 13/16 (81.25%) of the samples 
produced four fragment sizes at positions; 106bp, 190bp, 236bp and 568bp. This group of 
samples were assigned the code, Pattern 1. Two of the 16 samples (12.50%) produced three 
















GATGGTGTTT CCCACACAGTTCCAATTTAC GAAGGCTACT 
CCCTTCCACA CGCCATCATG AGACTTAACCTCGCTGGCCG 
TGATCTCACA GCCTGGATGG TCAAGCTTCT 
CACAGAGCGTGGCAATGCTT TCAACACAAC 
AGCCGAAAAG GAAATCGTTC 
GTGACATCAAGGAGAAGCTT TGCTATGTCG CCCTCGACTT 
CGATGCTGAA ATGGAGAAGGCCGCTACAGA 
CTCCTCCATC AACGTC 
386 HindII 687 none 1072 AACTACACAC TTCCAGATGG CAACGTCATC 
ACAATCGGCA ATGAGCGCTTCCGCTGCCCA GAAATGCTCT 
TCAAGCCATA CTTCGATGGT ATGGAATACGATGGTATCGA 
CAAGACACTC TTCGACTCCA TCATGAAGTG 
CGATATCGATGTTCGTAAGG ATCTCTACGC TAACATCGTT 
CTTTCTGGTG GCACAACAATGTTCCAAGGG CATCGCCGAA 
CGTCTTGACA AGGAAATCAC AGCTCTTGCTCCACCAACAA 
TGAAGGTCAA GATCGTCGCC CCAGAAGAGC 
GTAAGTACGCCGTTTGGGTC GGTGGCTCCA TCCTTGCTTC 
CCTCGCTACA TCCCACAGATGGGTATCACA 
AGGAGGAATA CGACGAGGCT GGTCTC 
200 none 1 HindII 200 ACGATACGCT CTGGTATGTG CAAGACGGCT 
TCTCTGGCGA TGAAGCCCCACGCTCTGTTT TTCCCATCCG 
TTGTTGGCCG ATCCAAAAGT ACAAACAACAATTAGTTGGT 
GGCAACGCCA AGGATGTCTT CGTCGGTGAT 
GAAGCTTGCTCCAAGGCTGG TGTCCTCATC CTCAAGTACC 
CAATTGAACA CGGTATCGTC 




four fragments at positions; 106bp, 190bp, 236bp and 452bp. The groups were assigned the 
codes, Pattern H and I, respectively (Table 6). The size of the digestion fragments obtained 






















Figure 11: RsaI RFLP pattern of the digested actin gene amplicon resolved on a 1.5% agarose 
gel. O’GeneRuler 50bp DNA Ladder (ThermoFisher Scientific) and banding profiles of the 


































































































































4.6.3 MseI profile  
For the MseI reactions, one sample did not produce a banding pattern despite numerous 
adjustments such as increased incubation time and increased amounts of template DNA. The 
sample produced a very faint uncut band. For the remaining 15/16 (93.75%) of the samples, an 
identical banding profile was observed for all the samples. Bands at positions 519bp and 581bp 
were observed (Figure 12). All of the samples producing a digestion pattern were assigned the 











Figure 12: MseI RFLP pattern of the digested actin gene amplicon resolved on a 1.5% agarose 
gel. M: 100bp DNA ladder (Thermofisher Scientific) and banding profiles of the clinical 
























































































































4.6.4 Frequency of genotypes 
According to the combined pattern codes of all three enzymes, genotype G was the most 
frequent genotype in our study population. A total of 13/16 (81.25%) of the samples contained 
this genotype. One sample (TV358) harboured genotype H. Similarly, one sample (TV211) 
harboured genotype I (6.25%). There was one sample (TV266) that could not be assigned a 
genotype since it lacked a banding profile for MseI, a pattern code could therefore not be 
determined. This sample was therefore excluded from further sequence analysis (Table 6).  
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Table 6: Fragment sizes obtained after digestion of the actin gene with the restriction enzymes HindII, MseI and RsaI as well as the assignment 














RsaI pattern Genotype 
TV4 60, 200 386,426 2 519,581 1 106,190,236,568 1 G 
TV9 60, 200 386,426 2 519, 581 1 106,190,236,568 1 G 
TV48 60, 200 386,426 2 519, 581 1 106,190,236,568 1 G 
TV79 60, 200 386,426 2 519, 581 1 106,190,236,568 1 G 
TV95 60, 200 386,426 2 519, 581 1 106,190,236,568 1 G 
TV128 60, 200 386,426 2 519, 581 1 106,190,236,568 1 G 
TV184 60, 200 386,426 2 519, 581 1 106,190,236,568 1 G 
TV211 60, 200 386,426 2 519, 581 1 106,190,236,452 3 I 
TV230 60, 200 386,426 2 519, 581 1 106,190,236,568 1 G 
TV232 60, 200 386,426 2 519, 581 1 106,190,236,568 1 G 
TV253 60, 200 386,426 2 519, 581 1 106,190,236,568 1 G 
TV266# 60, 200 386,426 2 -*  106,236,568 2 Could not be assigned 
TV270 60, 200 386,426 2 519, 581 1 106,190,236,568 1 G 
TV302 60, 200 386,426 2 519, 581 1 106,190,236,568 1 G 
TV357 60, 200 386,426 2 519, 581 1 106,190,236,568 1 G 
TV358 60, 200 386,426 2 519, 581 1 106,236,568 2 H 
 
* symbol indicates that no banding pattern was observed.  
 
# genotype could not be assigned due to no banding pattern for MseI
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4.7 Phylogenetic analysis of the actin open reading frame 
Translated nucleotide sequences obtained for the actin gene from nine clinical samples were 
edited and aligned with published sequences for genotypes G and H. There were no published 
sequences for genotype I to include in the comparative analysis. According to the multiple 
sequence alignment of the study samples with published T. vaginalis actin sequences, a total 
of four different single nucleotide changes in the open reading frame (ORF) of the actin gene 
were observed (Figure 13). Sample TV358 (genotype H) contained a single amino acid 
subsititution from Glutamine (Q) to Lysine (K). Sample TV184 (genotype G) also contained a 
single amino acid subsititution from Glutamic acid (E) to Arginine (R). Sample TV357 
(genotype G) contained two amino acid substitutions. The first change was the replacement of 
Leucine (L) with Arginine (R) and the second change was the replacement of Glycine (G) with 
Aspartic acid (D). The change from GD was also observed for a published T. vaginalis ATCC 
genotype G strain (EU076578) (Figure 13).  
 
 
TV270           -------HPSLSRPKYKQQLVGGNAKDVFVGDEACSKAGVLILKYPIEHGIVNNWDDMEK 
TV302           -------HPLFSRPKYKQQLVGGNAKDVFVGDEACSKAGVLILKYPIEHGIVNNWDDMEK 
TV230           ---------------------------------------------------------MEK 
TV232           ---------------------------------------------------------MEK 
TV211           ---------------------------------------------------------MEK 
TV358           -------IRLLARPKYKQQLVGGNAKDVFVGDEACSKAGVLILKYPIEHGIVNNWDDMEK 
KF747377        EAPRSVFPSVVGRPKYKQQLVGGNAKDVFVGDEACSKAGVLILKYPIEHGIVNNWDDMEK 
EU076579        EAPRSVFPSVVGRPKYKQQLVGGNAKDVFVGDEACSKAGVLILKYPIEHGIVNNWDDMEK 
EU076581        EAPRSVFPSVVGRPKYKQQLVGGNAKDVFVGDEACSKAGVLILKYPIEHGIVNNWDDMEK 
EU076578        EAPRSVFPSVVGRPKYKQQLVGGNAKDVFVGDEACSKAGVLILKYPIEHGIVNNWDDMEK 
TV357           EAPRSVFPSVVGRPKYKQQLVGGNAKDVFVGDEACSKAGVLILKYPIEHGIVNNWDDMEK 
TV184           ---------------------------------------------------------MEK 
TV253           ---------------------------------------------------------MEK 
                                                                         *** 
 
TV270           IWHHTFYNELRVDPTEHPVLLTEAPLNPKANREKMISLMFDTFNVPSFYVGIQAVLSLYS 
TV302           IWHHTFYNELRVDPTEHPVLLTEAPLNPKANREKMISLMFDTFNVPSFYVGIQAVLSLYS 
TV230           IWHHTFYNELRVDPTEHPVLLTEAPLNPKANREKMISLMFDTFNVPSFYVGIQAVLSLYS 
TV232           IWHHTFYNELRVDPTEHPVLLTEAPLNPKANREKMISLMFDTFNVPSFYVGIQAVLSLYS 
TV211           IWHHTFYNELRVDPTEHPVLLTEAPLNPKANREKMISLMFDTFNVPSFYVGIQAVLSLYS 
TV358           IWHHTFYNELRVDPTEHPVLLTEAPLNPKANREKMISLMFDTFNVPSFYVGIQAVLSLYS 
KF747377        IWHHTFYNELRVDPTEHPVLLTEAPLNPKANREKMISLMFDTFNVPSFYVGIQAVLSLYS 
EU076579        IWHHTFYNELRVDPTEHPVLLTEAPLNPKANREKMISLMFDTFNVPSFYVGIQAVLSLYS 
EU076581        IWHHTFYNELRVDPTEHPVLLTEAPLNPKANREKMISLMFDTFNVPSFYVGIQAVLSLYS 
EU076578        IWHHTFYNELRVDPTEHPVLLTEAPLNPKANREKMISLMFDTFNVPSFYVGIQAVLSLYS 
TV357           IWHHTFYNELRVDPTEHPVLLTEAPLNPKANREKMISLMFDTFNVPSFYVGIQAVLSLYS 
TV184           IWHHTFYNELRVDPTEHPVLLTEAPLNPKANREKMISLMFDTFNVPSFYVGIQAVLSLYS 
TV253           IWHHTFYNELRVDPTEHPVLLTEAPLNPKANREKMISLMFDTFNVPSFYVGIQAVLSLYS 




TV270           SGRTTGIVFDAGDGVSHTVPIYEGYSLPHAIMRLNLAGRDLTAWMVKLLTERGNAFNTTA 
TV302           SGRTTGIVFDAGDGVSHTVPIYEGYSLPHAIMRLNLAGRDLTAWMVKLLTERGNAFNTTA 
TV230           SGRTTGIVFDAGDGVSHTVPIYEGYSLPHAIMRLNLAGRDLTAWMVKLLTERGNAFNTTA 
TV232           SGRTTGIVFDAGDGVSHTVPIYEGYSLPHAIMRLNLAGRDLTAWMVKLLTERGNAFNTTA 
TV211           SGRTTGIVFDAGDGVSHTVPIYEGYSLPHAIMRLNLAGRDLTAWMVKLLTERGNAFNTTA 
TV358           SGRTTGIVFDAGDGVSHTVPIYEGYSLPHAIMRLNLAGRDLTAWMVKLLTERGNAFNTTA 
KF747377        SGRTTGIVFDAGDGVSHTVPIYEGYSLPHAIMRLNLAGRDLTAWMVKLLTERGNAFNTTA 
EU076579        SGRTTGIVFDAGDGVSHTVPIYEGYSLPHAIMRLNLAGRDLTAWMVKLLTERGNAFNTTA 
EU076581        SGRTTGIVFDAGDGVSHTVPIYEGYSLPHAIMRLNLAGRDLTAWMVKLLTERGNAFNTTA 
EU076578        SGRTTGIVFDAGDGVSHTVPIYEGYSLPHAIMRLNLAGRDLTAWMVKLLTERDNAFNTTA 
TV357           SGRTTGIVFDAGDGVSHTVPIYEGYSLPHAIMRRNLAGRDLTAWMVKLLTERDNAFNTTA 
TV184           SGRTTGIVFDAGDGVSHTVPIYEGYSLPHAIMRLNLAGRDLTAWMVKLLTERGNAFNTTA 
TV253           SGRTTGIVFDAGDGVSHTVPIYEGYSLPHAIMRLNLAGRDLTAWMVKLLTERGNAFNTTA 
                ********************************* ******************.******* 
 
TV270           EKEIVRDIKEKLCYVALDFDAEMEKAATDSSINVNYTLPDGNVITIGNERFRCPEMLFKP 
TV302           EKEIVRDIKEKLCYVALDFDAEMEKAATDSSINVNYTLPDGNVITIGNERFRCPEMLFKP 
TV230           EKEIVRDIKEKLCYVALDFDAEMEKAATDSSINVNYTLPDGNVITIGNERFRCPEMLFKP 
TV232           EKEIVRDIKEKLCYVALDFDAEMEKAATDSSINVNYTLPDGNVITIGNERFRCPEMLFKP 
TV211           EKEIVRDIKEKLCYVALDFDAEMEKAATDSSINVNYTLPDGNVITIGNERFRCPEMLFKP 
TV358           EKEIVRDIKEKLCYVALDFDAEMEKAATDSSINVNYTLPDGNVITIGNERFRCPEMLFKP 
KF747377        EKEIVRDIKEKLCYVALDFDAEMEKAATDSSINVNYTLPDGNVITIGNERFRCPEMLFKP 
EU076579        EKEIVRDIKEKLCYVALDFDAEMEKAATDSSINVNYTLPDGNVITIGNERFRCPEMLFKP 
EU076581        EKEIVRDIKEKLCYVALDFDAEMEKAATDSSINVNYTLPDGNVITIGNERFRCPEMLFKP 
EU076578        EKEIVRDIKEKLCYVALDFDAEMEKAATDSSINVNYTLPDGNVITIGNERFRCPEMLFKP 
TV357           EKEIVRDIKEKLCYVALDFDAEMEKAATDSSINVNYTLPDGNVITIGNERFRCPEMLFKP 
TV184           EKEIVRDIKEKLCYVALDFDAEMEKAATDSSINVNYTLPDGNVITIGNERFRCPEMLFKP 
TV253           EKEIVRDIKEKLCYVALDFDAEMEKAATDSSINVNYTLPDGNVITIGNERFRCPEMLFKP 
                ************************************************************ 
 
TV270           YFDGMEYDGIDKTLFDSIMKCDIDVRKDLYANIVLSGGTTMFQGIAERLDKEITALAPPT 
TV302           YFDGMEYDGIDKTLFDSIMKCDIDVRKDLYANIVLSGGTTMFQGIAERLDKEITALAPPT 
TV230           YFDGMEYDGIDKTLFDSIMKCDIDVRKDLYANIVLSGGTTMFQGIAERLDKEITALAPPT 
TV232           YFDGMEYDGIDKTLFDSIMKCDIDVRKDLYANIVLSGGTTMFQGIAERLDKEITALAPPT 
TV211           YFDGMEYDGIDKTLFDSIMKCDIDVRKDLYANIVLSGGTTMFQGIAERLDKEITALAPPT 
TV358           YFDGMEYDGIDKTLFDSIMKCDIDVRKDLYANIVLSGGTTMFKGIAERLDKEITALAPPT 
KF747377        YFDGMEYDGIDKTLFDSIMKCDIDVRKDLYANIVLSGGTTMFQGIAERLDKEITALAPPT 
EU076579        YFDGMEYDGIDKTLFDSIMKCDIDVRKDLYANIVLSGGTTMFQGIAERLDKEITALAPPT 
EU076581        YFDGMEYDGIDKTLFDSIMKCDIDVRKDLYANIVLSGGTTMFQGIAERLDKEITALAPPT 
EU076578        YFDGMEYDGIDKTLFDSIMKCDIDVRKDLYANIVLSGGTTMFQGIAERLDKEITALAPPT 
TV357           YFDGMEYDGIDKTLFDSIMKCDIDVRKDLYANIVLSGGTTMFQGIAERLDKEITALAPPT 
TV184           YFDGMEYDGIDKTLFDSIMKCDIDVRKDLYANIVLSGGTTMFQGHRRTS----------- 
TV253           YFDGMEYDGIDKTLFDSIMKCDIDVRKDLYANIVLSGGTTMFQGIAERLDKEITALAPPT 
                ******************************************:*  .              
 
Figure 13: Multiple sequence alignment of the actin ORF from clinical samples and published 
genotypes using Clustal W (GenomeNet). A total of 4 different single nucleotide changes in 
the open reading frame (ORF) of the actin gene were detected for the clinical samples (changes 
highlighted in yellow). A single change in one of the published sequences was also noted 




The phylogenetic analysis of the actin gene ORF from clinical samples and published 
genotypes showed the presence of distinct clusters. Overall, the majority of the samples 
analysed in this study were not closely related to any of the published sequences with the 
exception of samples TV357 and TV358 (Figure 14). The tree contained one cluster with only 
the clinical samples from this study with four samples from genotype G and the one sample 
from genotype I. This indicates that there was no significant diversity in the actin gene ORF of 
genotype I and certain genotype G samples. However, within the group of genotype G samples, 
a level of diversity was noted. Samples TV184, TV253 and TV357 did not cluster with the 
other genotype G samples. TV184 contained a single amino acid substitution (ER) which 
was not present in the other genotype G samples. Sample TV253 did not contain any 
substitutions, however, it did not cluster with the other samples of genotype without 
substitutions.  Sample TV357 was shown to cluster closely to the published G and H genotypes. 
This sample also carried two amino acid substitutions in the actin gene ORF (LR) and (G 
D). One of these substitutions (G D) was also observed for one of the published genotype 
G strains (EU076578). Sample TV358 (genotype H) clustered on its own. This sample also 




Figure 14: Phylogenetic tree of Trichomonas vaginalis actin genotypes according to the 
maximum-likelihood (ML), tree was conducted based on the multiple sequence alignment of 
actin gene by MEGA V10. Distance represents the number of base substitutions per site. 
4.8 Distribution of genotypes in relation to clinical symptoms  
For the one woman who carried genotype I, it was shown that this woman reported multiple 
symptoms associated with STIs such as abnormal vaginal discharge, foul-smelling vaginal 
odour, genital itching and genital warts (Table 7).  In the studied population, there was also one 
woman who harboured genotype H. This woman was asymptomatic (Table 7). For the women 
who harboured genotype G, it was shown that a large proportion of these women (53.8%) were 
asymptomatic; followed by 23.0% who reported symptoms of abnormal vaginal discharge; 
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15.3% reported genital itching; and 7.6% reported a combination of symptoms (abnormal 
vaginal discharge and genital itching (Table 7). 
Table 7: Genotypes linked to clinical symptoms of the studied population. 
Genotype Number of isolates Clinical symptoms reported 
I 1/1 (100%) Abnormal vaginal discharged, 
foul- smelling vaginal odour, 
genital itching and genital 
warts 
H 1/1 (100%)  No symptoms 
G 7/13 (53.85%) No symptoms 
G 3/13 (23.08%) Abnormal vaginal discharged 
G 2/13 (15.38%) Genital itching 
G 1/13 (7.69%)  Abnormal vaginal discharged 















Trichomoniasis is considered to be the most prevalent non-viral sexually transmitted infection 
(STI) worldwide affecting individuals of all ages, ethnicity and socioeconomic groups 
(Napierala et al., 2010; Conrad et al., 2012; Apalata et al., 2014; Naidoo, 2015).  The global 
prevalence rates for T.vaginalis varies between 0.9%-80% (Valadkhani et al., 2008; Javanbakht 
et al., 2013; Abou-Kamar et al., 2017).  
In this study, the prevalence of T. vaginalis in the antenatal women was approximately 13.0% 
(47/362).  A similar prevalence rate of 10% for T.vaginalis was observed for antenatal women 
from Durban (Dessai et al., 2020).  The prevalence estimates reported in South African women 
correlates with the rates reported for other African countries. A study conducted by Abou-
Kamar et.al, 2017 in Egypt on pregnant and non-pregnant women, showed a prevalence rate 
of 13.5% for T. vaginalis. An earlier study conducted by the WHO in the African region in 
women aged 15 to 49 years of age reported an estimated prevalence rate of 11.5% for T. 
vaginalis infection (Newman et al., 2015).  
Approximately 50% of women infected with T. vaginalis are asymptomatic (Sood and Kapil, 
2008; Donbraye et al., 2010). In the present study, the majority of the antenatal women (57. 
4%) were asymptomatic (no abnormal vaginal discharge) yet tested positive for T. vaginalis.  
Similarly, De Waaij et al., 2017, reported that 66% of the South African women in their study 
were asymptomatic.  
Overall, the median age of the women who tested positive for T. vaginalis in this study was 
28.0 (24.0-32.5). The majority of the study women had completed high school (68.1%), were 
unmarried (91.5%), had a regular sex partner (80.9%), had between 2-4 lifetime sex partners 
(66.0%) and were in the last trimester of pregnancy (59.6%). However, there were no 
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significant associations between these variables and T. vaginalis positivity. Shahraki et al., 
2020 reported no relation between the T. vaginalis infection rates and educational level which 
is consistent with our findings.  However, Munoz-Ramírez et al., 2018 reported that younger 
women (21-30 years) had the highest T. vaginalis infection rate when compared to women over 
30 years of age. In a study by De Lemos and Garcia-Zapata, 2010, early sexual debut was 
associated with T. vaginalis infection rates and Donbraye et al., 2010, reported that the 
trimester of pregnancy may contribute to the prevalence rates of T. vaginalis.  
The genetic characterization of T. vaginalis isolates from various regions show that there is 
significant genetic diversity in this organism (Meade and Carlton, 2013). Currently, there is a 
lack of data on the circulating genotypes of T. vaginalis in South African populations, 
particularly pregnant women. This was the first South African study, to employ the Polymerase 
Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP) of the actin gene to 
identify the different genotypes of T. vaginalis circulating in our population. 
T. vaginalis is said to contain an actin protein which is coded by a 9-membered family, having 
nucleotide resemblances in 5 genes which are similar to mammalian actin genes.                    
When T. vaginalis attaches to the surface of the host cell, it causes the parasite to transform 
from a tetanus form to amoebic form resulting in appendage formation i.e. pseudopodia 
(Shahraki et al., 2020). Both attachment and deformation regarding the host cell can be 
associated with the pathogenicity of T. vaginalis. The actin gene thus, plays a significant role 
in the parasite’s pathogenicity thereby making it the gene of choice for molecular typing 
techniques (Rezaeian et al., 2009; Menendez et al., 2010; Shahraki et al., 2020). 
In this study, three different genotypes of T. vaginalis were identified by PCR-RFLP of the 
actin gene. The most frequent genotype in our study population was the genotype G. Other      
T. vaginalis genetic studies conducted on the African continent revealed the presence of 
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genotypes G and E as highly prevalent (Crucitti et al., 2008; Masha et al., 2017). A study 
conducted in the Democratic Republic of Congo (DRC) and Zambia on female sex workers 
revealed the presence of eight different genotypes based on the actin gene. In the DRC, the 
most prevalent genotype was E, whereas in Zambia the most common genotype was G (Crucitti 
et al., 2008). Our study findings are consistent with the findings from Zambia.  A study 
conducted on pregnant women from Kenya, reported a high frequency of genotype E (Masha 
et al., 2017) which is similar to the results obtained for the DRC (Crucitti et al., 2008). From 
the above-mentioned studies it is evident that common genotypes of T. vaginalis are circulating 
in various population groups across the African continent. In a study conducted in Ndola, 
Zambia involving adolescent girls, pregnant women as well as sex workers, Crucitti et al., 
2010, identified nine different genotypes, with genotype G being the most frequent across all 
three study groups. This is similar to the findings of the pregnant women tested in the current 
study.   
In studies conducted out of Africa, Momeni et al., 2015, identified five different genotypes 
with genotype G being the most prevalent in a population of Iranian men and women. However, 
three recent studies conducted in Iran (Matini et al., 2017; Khalili et al., 2017; Oliaee et al., 
2017) observed a high prevalence of T. vaginalis genotypes which differed from the genotypes 
observed in Africa and those reported by Momeni et al., 2015 for Iran. Matini et al., 2017, 
investigated the prevalence of T. vaginalis genotypes in symptomatic and asymptomatic 
women, attending Gynaecology Clinics in western Iran.  According to the actin gene digestion 
profiles, genotype A was shown to be the most prevalent in their study population (Matini et 
al., 2017).  A study conducted on women seeking care in a general clinic in southwestern Iran, 
reported on genotype H as being the most frequent (Khalili et al., 2017). Similar findings were 
reported by Oliaee et al., 2017 in a population of incarcerated women from southern Iran where 
genotype H was shown to be the most frequent (Oliaee et al., 2017).   
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In this study, within the samples that belonged to genotype G, a level of diversity was noted as 
evidenced by the multiple sequence alignments and phylogenetic analyses. Three samples 
TV184, TV253 and TV357 did not cluster with the other genotype G samples. The possibility 
of obtaining different genotypes involving T. vaginalis within a study population could be due 
to large sample numbers as well as obtaining samples from regions which have a much higher 
prevalence rate (Abou-kamar et al., 2017). In this study, the prevalence of T. vaginalis was 
close to 13% and this relatively high prevalence could have contributed to the observed 
diversity. In addition, for the women who carried genotype G, it was shown that a large 
proportion of these women (53.8%) were asymptomatic; followed by 23.0% who reported 
symptoms of abnormal vaginal discharge; 15.3% reported genital itching; and 7.6% reported a 
combination of symptoms (abnormal vaginal discharge and genital itching). A study conducted 
by Khalili et al., 2017 also showed that in the group of women who carried genotype G there 
was a combination of women who were asymptomatic as well as symptomatic. It is possible 
that the genetic differences in the pathogen may contribute to the clinical manifestations 
associated with infection. However, this will need to be confirmed by further investigations.  
Within the genotype G study samples, two of the three samples carried amino acid substitutions 
in the actin gene ORF. One particular sample TV357 showed a replacement of Leucine (L) 
with Arginine (R) and replacement of Glycine (G) with Aspartic acid (D). Similar findings 
were reported by Spotin et al., 2016 for a T.vaginalis isolate from Iran. The multiple alignment 
of the Iranian isolate which was assigned genotype G showed amino acid substitutions where 
Aspartic acid (D) replaced Glycine (G) and Arginine (R) replaced Leucine (L) (Spotin et al., 
2016). This indicates that there may be a small level of similarity between T. vaginalis genotype 
G samples from different regions. 
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This study was limited in terms of the small sample size used for the genotyping analysis and 
sampling of only one region within KwaZulu-Natal. A larger sample size from a wider 
population is needed to obtain more substantial evidence on the diversity of this pathogen. This 
is a future study that our research group is embarking on. In addition, the actin genes were not 
shown to be present in all positive samples which is an unexpected finding, this could be due 
to technical errors during sample processing which will need to be investigated.  
Future work emanating from this study, would be to investigate the association of the genotypes 
with patterns of drug susceptibility in this protozoa. In addition, it would be useful to compare 
the distribution of the genotypes in pregnant and non-pregnant populations. It may also be 
useful to look at the association of the genotypes with the prevalence of the different T. 


















Early techniques which were applied for the typing of T. vaginalis isolates included, antigenic 
characterisation, monoclonal antibody binding (Krieger), karyotype polymorphism by pulsed 
field gel electrophoresis, random amplified polymorphic DNA (RAPD), and restriction 
fragment length polymorphism (RFLP). Despite the numerous list of typing techniques, each 
of the above-mentioned had significant limitations (Meade and Carlton, 2013). Currently, the 
PCR-RFLP technique based on the actin gene amplification provides a sensitive and reliable 
method for typing of T. vaginalis isolates (Oliaee et al., 2017). 
 
The present study provides evidence on the genetic diversity of T. vaginalis from a South 
African pregnant population based on typing of the actin gene. Three different genotypes were 
observed in the studied population. Within the dominant genotype, i.e. genotype G, diversity 
in the actin gene ORF of the samples harbouring this genotype was observed. The observed 
diversity within specific populations can be challenging for future vaccine design and 
development of antigen-based rapid diagnostic tests for trichomoniasis.  Future vaccine design 
studies and diagnostic studies will need to direct their focus on identifying antigenic 
determinants which are broadly representative of the entire T. vaginalis population (Meade and 
Carlton, 2013). However, one of our South African isolates was closely related to an Iranian 
isolate. This holds some promise that there may be conserved T. vaginalis isolates from 
different geographical regions. This could lend some hope for future vaccine design and 
diagnostic studies focused on identifying antigenic determinants which are broadly 
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Table 1: DNA Concentration (ng/µl) and DNA purity for positive T. vaginalis samples  
Sample TaqMan result Actin result DNA Concentration 
(ng/µl) 
DNA purity 
3 + - 1.1 1.82 
4 +  + 3.2 1.03 
5 + - 15.3 1.82 
9 + + 35.9 1.88 
11 + - 6.0 1.97 
38 + - 4.6 0.74 
48 + + 0.4 0.0 
50 + - 8.8 2.29 
52 + - 52.5 1.81 
53 + - 48.3 1.79 
79 + + 16.6 1.55 
91 + - 11.0 1.07 
94 + - 6.1 1.00 
95 + + 62.4 1.80 
103 + - 6.9 1.55 
104 + - 3.4 0.83 
128 + + 5.2 1.44 
134 + - 10.8 1.55 
135 + - 8.1 1.42 
137 + - 7.2 1.68 
173 + - 9.8 1.32 
181 + - 6.4 1.70 
182 + - 5.6 1.39 
184 + + 7.8 1.66 
205 + - 30.3 1.84 
210 + - 5.6 1.57 
211 + + 50.0 1.90 
213 + - 8.5 1.53 
230 + + 5.2 1.38 
232 + + 9.8 1.39 
233 + - 2.7 0.99 
243 + - 9.9 1.38 
253 + + 6.3 1.47 
255 + - 6.1 1.89 
266 + + 18.1 1.74 
269 + - 13.1 1.68 
270 + + 17.8 1.71 
277 + - 18.9 1.75 
302 + + 2.2 1.47 
305 + - 17.6 1.53 
331 + - 16.1 1.70 
342 + - 5.8 1.59 
357 + + 2.5 1.57 
358 + + 3.1 1.32 
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359 + - 2.6 1.81 
360 + - 7.6 1.60 
362 + - 4.2 1.76 
 
 Symbols: (+) Positive   
                  (-) Negative  



















T. vaginalis genotyping identification 




All 362 DNA samples were subjected to TaqMan quantitative PCR assay for the detection of 




Positive samples 3, 4, 5, 9, 11, 38, 48, 50, 52, 53, 79, 91, 94, 95, 103, 104, 128, 134, 135, 
137, 173, 181, 182, 184, 205, 210, 211, 213, 230, 232, 233, 243, 253, 255, 266, 269, 270, 




Positive samples were then used for the amplification of the outer and inner actin genes. Only 









Genotyping of the actin gene was performed using the restriction fragment length 
polymorphisms (RFLP) technique. Restriction enzymes, HindII, MseI, and RsaI were used, 
resulting in the identification of three genotypes G, H and I. 
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